What is the standard Epitalon dosage?

There is no evidence-based standard Epitalon dosage. One small human study exposed 20 participants to 0.5 mg of synthetic AEDG per day under the tongue for 20 days, but it did not compare doses or establish a subcutaneous schedule. A prescriber must set the substance, route, amount, frequency and course length for the formulation actually dispensed.

Are Epitalon and epithalamin the same substance?

Epitalon and epithalamin are different substances. Epitalon is the defined synthetic tetrapeptide Ala-Glu-Asp-Gly, while epithalamin is a polypeptide mixture extracted from animal pineal tissue. Older human studies often used the extract, including repeated 10 mg courses. Those milligram amounts cannot be copied or converted directly into a dose of synthetic Epitalon.

How often is an Epitalon course repeated?

No trial has established an optimal repeat interval. Compounded orders are often written as a short, finite course with months off before reassessment, partly echoing older research designs. The published patterns range from a single 20-day human sublingual exposure to monthly mouse courses and six-month epithalamin intervals, so repetition is a prescriber decision rather than a standard cycle.

Can an Epitalon animal dose be converted to a human dose?

Animal doses cannot be converted directly into a personal human dose. The 2003 mouse study used 1 microgram per mouse, about 30–40 micrograms/kg, on five consecutive days each month. Differences in species, route, metabolism and study purpose make simple body-weight scaling unreliable, and no human pharmacokinetic or dose-ranging study validates such a conversion.

What is Epitalon's FDA status?

No. Epitalon is not FDA-approved for any use. A federal advisory committee recommended Epitalon for the 503A bulk-substances list in July 2026, but that vote was advisory and rulemaking was still pending on August 25, 2026. Listing eligibility and approval of a finished drug are different regulatory questions.

Who sets the dose for compounded Epithalon?

The licensed prescriber sets the dose for the exact formulation a compounding pharmacy will dispense. The order should identify the chemical form, concentration, route, amount, frequency, number of days and refill status. Published human, animal and epithalamin schedules provide context, but none supplies a validated universal injection protocol for synthetic Epithalon.

Epitalon Dosage: How a Prescriber Decides

There is no evidence-based standard epitalon dosage. The only dosing numbers worth quoting come with major limits: one small human study used synthetic AEDG under the tongue for 20 days, while the widely repeated injection-cycle pattern often traces to animal work or older human studies of epithalamin, a different pineal extract. A prescriber therefore decides the substance, route, strength, course length and whether any course should repeat; the literature does not supply a validated self-directed protocol.

First identify the substance

Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly, or AEDG. Epithalamin is a mixture of polypeptides extracted from animal pineal tissue. The names look interchangeable in older summaries, but the substances are not. FDA's 2026 review made that distinction explicit.

That matters because a milligram of an extract is not a milligram of a defined four-amino-acid peptide. A course studied with epithalamin cannot be converted into an Epitalon course by copying the number. The free-base and acetate forms of Epitalon are also distinct bulk drug substances, so the prescription and pharmacy label must identify what is actually being dispensed.

This page stays with dose selection and evidence limits. The separate Epitalon benefits review owns the question of what outcomes have been studied, while the Epithalon product page explains the prescription route.

What the epitalon dosage evidence actually used

The published schedules do not form one coherent dose ladder. They differ by species, substance and route.

Evidence source	Substance and population	Schedule reported	What it can establish
Ivko and colleagues, 2020	Synthetic AEDG; 20 middle-aged night-shift workers with low melatonin-metabolite excretion received active treatment	0.5 mg per day under the tongue for 20 days	One short human exposure pattern; not an injection dose-finding study
Anisimov and colleagues, 2003	Synthetic Epitalon; 54 treated female mice	1 microgram per mouse, about 30–40 micrograms/kg, by subcutaneous injection on five consecutive days each month from age 3 months until natural death	An animal regimen; not a human conversion formula
Korkushko and colleagues, 2011	Epithalamin extract; 39 older coronary patients	10 mg intramuscularly every three days for five injections per course, repeated at six-month intervals for six courses over three years	A repeated-course design for a different substance, not synthetic Epitalon dosing

Why these schedules do not convert

In the small human AEDG study, the active course lasted 20 days and the route was sublingual. The PubMed record for the study reports changes in a urinary melatonin metabolite and circadian-gene expression, but it was not designed to compare doses or establish an injectable regimen. FDA's later review noted that the paper did not report safety data.

The monthly mouse schedule came from a 2003 Biogerontology experiment. Its microgram-per-mouse exposure cannot be scaled into a personal injection order. The long human course is equally easy to misread: the 2011 randomized comparative study used six courses of epithalamin over three years. Its extract dose does not validate the same milligram number for AEDG.

Why compounded courses are written individually

Compounded orders are commonly framed as a finite course followed by time off, with a provider deciding later whether another course is appropriate. That short-course language resembles parts of the research record. It is still a prescribing convention, not a protocol proved by a dose-ranging trial.

A complete order has to settle more than a daily amount. It identifies the exact bulk substance, concentration, route, amount per administration, frequency, number of treatment days and whether refills are authorized. Those choices cannot be separated from the pharmacy's formulation and beyond-use date. How often peptide injections are scheduled explains the difference between injection frequency and total course length more broadly.

The missing evidence is as important as the available numbers. There is no published human pharmacokinetic study defining how Epitalon is absorbed, cleared or accumulated, no maximum tolerated dose and no human comparison of short versus repeated subcutaneous courses. More frequent or longer exposure therefore cannot be presumed equivalent to a published schedule.

What a prescriber weighs

Dose selection starts with whether the request is medically coherent. The reviewing clinician considers health history, current medicines, pregnancy or breastfeeding, the proposed route, prior reactions to injected products and whether a different evaluation is needed for the symptom being discussed. Active or recent malignancy deserves particular attention because FDA's review identified unresolved questions around chronic exposure and telomerase-related mechanisms; it did not identify human safety studies that could settle them.

Product identity also matters. Grey-market vials may use the same common name for different chemical forms and provide no accountable clinician or dispensing record. A prescription filled by a licensed U.S. compounding pharmacy creates a documented chain from the clinician's order to the labeled vial. How a peptide compounding pharmacy works covers that quality and accountability question in detail.

Regulatory status as of August 25, 2026

Epitalon is not FDA-approved for any use. On July 24, 2026, the Pharmacy Compounding Advisory Committee recommended Epitalon for the 503A bulk-substances list, as The BMJ reported. The vote was advisory. It did not add either substance to the list or approve a finished medication, and rulemaking remained pending as of August 25, 2026.

The FDA meeting record shows that the agency evaluated the substances for insomnia. The FDA briefing document found no human subcutaneous safety study, no human pharmacokinetic data and no clinical trial of Epitalon for insomnia. The committee's recommendation and FDA staff's evidence assessment are separate facts.

Regulatory status is one input into a prescribing decision, not a marketing gate. A licensed provider may still prescribe a compounded formulation where permitted, and that decision belongs to the patient and prescriber.

What the dosing conversation should settle

A sound dosing discussion should end with five unambiguous facts: which Epitalon form the pharmacy will use, the route, the prescribed amount and frequency, the finite course length, and the conditions for stopping or reconsidering another course. It should also make clear that the human sublingual study, mouse schedule and epithalamin courses are context rather than instructions. The clinical record should identify who answers questions during the course and what change would prompt review before the planned end date.

At Promise, a licensed provider reviews every request and decides whether Epithalon is appropriate; not everyone qualifies. The prescriber's written order and pharmacy label, rather than a protocol copied from the internet, set the actual dose.